Literature DB >> 19782408

Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.

Amer Awad1, Bernhard Hemmer, Hans-Peter Hartung, Bernd Kieseier, Jeffrey L Bennett, Olaf Stuve.   

Abstract

The laboratory evaluation of cerebrospinal fluid (CSF) has been routinely employed as a diagnostic test in the diagnosis of neuroimmunological disorders such as multiple sclerosis (MS). Recently, CSF analyses in MS have garnered renewed interest as a tool for monitoring disease activity and prognosis. With the identification of patients that are very early in their disease course, namely patients with a radiologically isolated (RIS) or a clinically isolated syndrome (CIS), the true value of these evaluations has yet to be fully explored. Ultimately, the hope is that biomarkers within this compartment will be identified that will identify etiologic factors of MS and other inflammatory disorders of the central nervous system. In this review we discuss the history of CSF diagnostic tests and the most recent methodological advances. We also outline the potentially important diagnostic role and possible limitations of these tests. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782408     DOI: 10.1016/j.jneuroim.2009.09.002

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  23 in total

Review 1.  Distinguishing Susac's syndrome from multiple sclerosis.

Authors:  Katherine A Buzzard; Stephen W Reddel; Con Yiannikas; D Sean Riminton; Michael H Barnett; Todd A Hardy
Journal:  J Neurol       Date:  2014-12-30       Impact factor: 4.849

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.

Authors:  Simone M Brändle; Birgit Obermeier; Makbule Senel; Jessica Bruder; Reinhard Mentele; Mohsen Khademi; Tomas Olsson; Hayrettin Tumani; Wolfgang Kristoferitsch; Friedrich Lottspeich; Hartmut Wekerle; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-20       Impact factor: 11.205

4.  Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Mahlon A Collins; Jiyan An; Brian L Hood; Thomas P Conrads; Robert P Bowser
Journal:  J Proteome Res       Date:  2015-10-08       Impact factor: 4.466

5.  Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis.

Authors:  Kathryn M Brennan; Francesc Galban-Horcajo; Simon Rinaldi; Colin P O'Leary; Carl S Goodyear; Gabriela Kalna; Ariel Arthur; Christina Elliot; Sue Barnett; Christopher Linington; Jeffrey L Bennett; Gregory P Owens; Hugh J Willison
Journal:  J Neuroimmunol       Date:  2011-08-26       Impact factor: 3.478

Review 6.  Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space.

Authors:  Achilles Ntranos; Fred Lublin
Journal:  Curr Neurol Neurosci Rep       Date:  2016-10       Impact factor: 5.081

7.  Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.

Authors:  Jacqueline F Marcus; Emmanuelle L Waubant
Journal:  Neurohospitalist       Date:  2013-04

8.  MicroRNAs and Multiple Sclerosis.

Authors:  Kemal Ugur Tufekci; Meryem Gulfem Oner; Sermin Genc; Kursad Genc
Journal:  Autoimmune Dis       Date:  2010-11-11

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial.

Authors:  Harald Prüss; Berit Rosche; Aaron B Sullivan; Benedikt Brommer; Oliver Wengert; Karsten Gronert; Jan M Schwab
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.